583 Results for "

JAK2/ACVR1 (ALK2)/ALK5 inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (583)

583 Results for "JAK2/ACVR1 (ALK2)/ALK5 inhibitor" in MCE Product Catalog:

819
819 Publications Verification
Cat. No.: HY-13418
CAS No.: 1219168-18-9
Purity:  99.7%
Synonyms: Compound C dihydrochloride; BML-275 dihydrochloride
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
loading...
    loading...
819
819 Publications Verification
Cat. No.: HY-13418A
CAS No.: 866405-64-3
Purity:  99.10%
Synonyms: BML-275
Research Areas:  

Cancer

Dorsomorphin (BML-275) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599) [1] [2].
loading...
    loading...
323
323 Cited Publications
Cat. No.: HY-10431
CAS No.: 301836-41-9
Purity:  99.85%
Research Areas:  

Cancer

SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways [1] [2] .
loading...
    loading...
173
173 Cited Publications
Cat. No.: HY-12000
CAS No.: 133550-30-8
Purity:  99.86%
Synonyms: Tyrphostin AG490; Tyrphostin B42
Target:  

EGFR STAT JAK Autophagy

Research Areas:  

Cancer

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
loading...
    loading...
144
144 Cited Publications
Cat. No.: HY-10432A
CAS No.: 2828431-89-4
Purity:  98.43%
Research Areas:  

Cancer

A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively [1].
loading...
    loading...
144
144 Cited Publications
Cat. No.: HY-10432
CAS No.: 909910-43-6
Purity:  99.33%
Research Areas:  

Cancer

A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively [1].
loading...
    loading...
103
103 Cited Publications
Cat. No.: HY-40354
CAS No.: 477600-75-2
Synonyms: Tasocitinib; CP-690550
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [1] [2] [5] .
loading...
    loading...
103
103 Cited Publications
Cat. No.: HY-40354A
CAS No.: 540737-29-9
Synonyms: Tasocitinib citrate; CP-690550 citrate
Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [1] [2] [5] .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071
CAS No.: 1062368-24-4
Purity:  99.41%
Synonyms: DM-3189
Research Areas:  

Cancer

LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva [1] [2] .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071A
CAS No.: 2310134-98-4
Purity:  99.79%
Synonyms: DM-3189 Tetrahydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) Tetrahydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva [1] [2] .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071B
CAS No.: 1435934-00-1
Purity:  99.75%
Synonyms: DM-3189 dihydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) dihydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva [1] [2] .
loading...
    loading...
82
82 Cited Publications
Cat. No.: HY-15315A
CAS No.: 1187595-84-1
Purity:  99.97%
Synonyms: LY3009104 phosphate; INCB028050 phosphate
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.
loading...
    loading...
82
82 Cited Publications
Cat. No.: HY-15315
CAS No.: 1187594-09-7
Purity:  99.93%
Synonyms: LY3009104; INCB028050
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
loading...
    loading...
82
82 Cited Publications
Cat. No.: HY-12071C
CAS No.: 1062368-62-0
Synonyms: DM-3189 hydrochloride
LDN193189 (DM-3189) hydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva [1] [2] .
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-10409
CAS No.: 936091-26-8
Purity:  99.83%
Synonyms: TG-101348; SAR 302503
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research [1] [2].
loading...
    loading...
55
55 Cited Publications
Cat. No.: HY-10409A
CAS No.: 1374744-69-0
Purity:  99.92%
Synonyms: TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research [1] [2].
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-15312
CAS No.: 857064-38-1
Purity:  99.77%
Target:  

STAT JAK Apoptosis

Research Areas:  

Cancer

WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3. WP1066 can cross the blood-brain barrier[1][2][3][4].
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-16954
CAS No.: 1818885-28-7
ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma [1] [2] [5] .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-N7452
CAS No.: 4434-05-3
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-19569
CAS No.: 1310726-60-3
Synonyms: ABT-494
Target:  

JAK

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research [1] [2].
loading...
    loading...